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A series of tetrapeptide amides containing two aminoisobutyric acids (Aib) and two α-methylphenylalanine ((αMe)Phe) units were prepared 
via the ‘azirine/oxazolone method’. New 2-benzyl-2-methyl-2H-azirine-3-amines have been used for the selective introduction of (S)- and 
(R)-(αMe)Phe, respectively. The solid-state conformations of five tetrapeptide amides were determined by X-ray crystallography. In all cases, 
two β-turns stabilize 310-helical conformations and it was confirmed that, in contrast to proteinogenic amino acids, the configuration of 
(αMe)Phe does not determine the screw sense of the helix. 
Keywords: 2H-azirin-3-amines • X-ray crystallography • α-methylphenylalanine • azirine/oxazolone method • peptide conformation 
 
Introduction 
Peptides containing 2-aminoisobutyric acid (Aib) units attract strong interest because of their chemical and biological properties. A well-
known example is alamethicin,[1–5] a membrane-channel forming peptaibol[6–13] with antibiotic activities. We have shown that the 
‘azirine/oxazolone method’ [14–18] is a convenient approach for the synthesis of Aib-containing oligopeptides[15, 19–24] and peptaibols.[25–32] In 
addition to Aib, peptaibols may also contain the chiral α,α-disubstituted α-amino acid isovaline (Iva).[33–38] In a series of studies of model 
peptides consisting of Aib and Iva residues[39,40] and of Iva homopeptides[41–43] it was shown that there is no unambiguous correlation between 
the configuration of Iva and the screw sense of the helical structure. Furthermore, α-methylphenylalanine ((αMe)Phe) has been studied 
intensely as a prototype of chiral α,α-disubstituted α-amino acids,[44–52] for example the influence of its configuration on the conformation of 
peptides.[53–59] For this reason, the synthesis of 3-amino-2H-azirines with two different substituents at C(2) and their use in peptide synthesis 
was an attractive challenge. Thus, the preparation of racemic synthons for Iva[60] and (αMe)Phe[61] was elaborated in our group and their 
convenient use in peptide synthesis has been demonstrated.[20,21,30,32,62–65] Furthermore, analogous optically active 3-amino-2H-azirines of type 
1 – 3 (Fig. 1) bearing a chiral substituent at the amino group were obtained after chromatographic separation of the corresponding 
diastereomeric mixtures.[66–68]  
 
 
Figure 1. 3-Amino-2H-azirines as synthons for enantiomerically pure Iva and (α-Me)Phe. 
The goal of the present study was the preparation of the enantiomerically pure (α-Me)Phe synthons (R,R)- and (S,R)-2a and their 
use in the synthesis of diverse tetrapeptide derivatives containing two Aib and two (αMe)Phe residues. Furthermore, the solid state 




Results and Discussion 
Synthesis of Tetrapeptide Amides Containing two Aib and two (αMe)Phe Units. 
 
In analogy to the earlier published preparation of synthons for (R)- and (S)-(αMe)Phe of type 2[67] or 3[68], the desired 3-amino-2H-azirines 
(R,R)- and (S,R)-2a were synthesized as a ca. (1:1)-mixture by starting with the previously described propanamide (R)-4[66] (Scheme 1). 
Benzylation of (R)-4 and subsequent reaction with Lawesson reagent (L.R.) led to a (1:1)-mixture of the thioamides (R,R)- and (S,R)-6, 
which could be separated chromatographically in small amounts for analytical purposes. Consecutive treatment of the mixture in 
CH2Cl2/DMF with COCl2 (toluene solution), deprotonation with 1,4-diazabicyclo[2.2.2]octane (DABCO) in THF, and reaction with NaN3 
gave a (1:1)-mixture of the azirines (R,R)- and (S,R)-2a, which were separated chromatographically (MPLC). Based on the X-ray crystal 
structures of the subsequently prepared peptides, the configuration of the less polar diastereomer was elucidated as S,R. 
 
 
Scheme 1. Synthesis of the 3-amino-2H-azirines (R,R)- and (S,R)-2a as (αMe)Phe synthons. 
With the (αMe)Phe synthons 2a and 3 in hand, a series of tetrapeptide derivatives with different sequences of two Aib and two 
(αMe)Phe units were prepared by using the ‘azirine/oxazolone method’. The selected approach to Aib-(αMe)Phe-Aib-(αMe)Phe peptides 
with an alternating sequence of the two amino acids is shown in Scheme 2. Reaction of Z-Aib-OH with aminoazirine (S,S)-3,[68] followed by 
selective hydrolysis of the C-terminal amide group, gave the dipeptide (S)-8 in high yield. Subsequent azirine coupling with the Aib-synthon 
9 led to the tripeptide amide (S)-10, which was hydrolyzed to yield tripeptide (S)-11. The latter was coupled with the (αMe)Phe-synthons 




1) In preliminary experiments, the azirine coupling of (S)-11 was also tested with the synthons (S,S)- and (R,S)-3 in CHCl3. The reactions 




Scheme 2. Synthesis of tetrapeptides 12 and 13 with alternating Aib and (αMe)Phe units by the ‘azirine/oxazolone method’. 
 
Whereas crystallization of (S,S,R)-12 from AcOEt/hexane yielded crystals of good quality for X-ray crystallography, those of the 
diastereomer (S,R,R)-12 were only weakly diffracting. For this reason and with the aim of testing a possible influence of the N-terminal 
carbonyl function on the conformation of the tetrapeptide, the N-terminus of (S,R,R)-12 was deprotected by treatment with ammonium 
formate and Pd/C in boiling methanol.[69] The crude product was dissolved in AcOEt/Et3N and reacted with 4-bromobenzoyl chloride to give 
(S,R,R)-13 in 90% yield. Suitable crystals for the X-ray analysis of the latter were obtained from AcOEt/petroleum ether. 
The synthesis of the next two tetrapeptide amides with two (αMe)Phe units inserted in positions two and three is presented in 
Scheme 3. Starting with dipeptide (S)-8, azirine coupling with the racemic (αMe)Phe-synthon rac-14[70] in CH2Cl2 occurred smoothly at 
room temperature to give a ca. (1:1)-mixture of the diastereomers (S,R)- and (S,S)-15 in 96% yield.2) These two tripeptide amides were 
separated chromatographically (MPLC, AcOEt) and were obtained as pure diastereomers (S,R)-15 and (S,S)-15 in 35 and 37% yield, 





2) The attempted coupling of (S)-8 with the (αMe)Phe-synthons (S,S)- and (R,S)-3, respectively, was unsuccessful. The azirines decomposed 
partially under the reaction conditions (CH2Cl2, 0 °C to r.t.). On the other hand, the tested coupling with (S,R)-2a and (R,R)-2a, respectively, 






Scheme 3. Synthesis of tetrapeptides 16 and 17 with accumulated (aMe)Phe units by the ‘azirine/oxazolone method’. 
 
 
Each of the two tripeptides 15 was hydrolyzed and coupled with the Aib-synthon 9 under the usual conditions to give the desired 
tetrapeptide amides (S,R)- and (S,S)-16 in 92 and 90% yield, respectively. Crystallization of (S,S)-16 from AcOEt/hexane led to suitable 
crystals for an X-ray structure determination. The diastereomer (S,R)-16 was transformed into the 4-bromobenzoyl-protected derivative 
(S,R)-17, which also gave crystals of good quality. 
Finally, two tetrapeptides with two Aib moieties in positions two and three and an (αMe)Phe unit in positions one and four were 
prepared according to Scheme 4. Reaction of 4-bromobenzoic acid with (R,S)-3[68] in THF led to the protected (αMe)Phe amide (R,S)-18 in 
45% yield. The molecular structure and configuration of this compound were established by X-ray single-crystal analysis (Fig. 2). The 
compound in the crystal is enantiomerically pure and the absolute configuration has been determined independently by the diffraction 
experiment. The molecules are linked by intermolecular N(1)–H….O(2’) hydrogen bonds to form extended chains, which run parallel to the 










Figure 2. ORTEP Plot[71] of the molecular structure of (αMe)Phe derivative (R,S)-18 (50% probability ellipsoids; arbitrary numbering of 
atoms; H-atoms bonded to C-atoms have been omitted for clarity) 
 
Selective hydrolysis of (R,S)-18 under the usual conditions, subsequent coupling of the crude (αMe)Phe acid with azirine 9 as Aib 
synthon, again hydrolysis and coupling with 9 gave the tripeptide amide (R)-19 in 77% yield. The latter was once more hydrolyzed and 
reacted with the (αMe)Phe synthons (S,R)- and (R,R)-2a, respectively, which lead to the desired tetrapeptide derivatives (R,S,R)- and 
(R,R,R)-20 in 95 and 87% yield, respectively. 
 
Crystal Structures of Tetrapeptide Amides Containing two Aib and two (αMe)Phe Units. 
 
The structures and solid state conformations of three Aib-(αMe)Phe-Aib-(αMe)Phe derivatives and two Aib-(αMe)Phe-(αMe)Phe-Aib 
derivatives have been determined by single crystal X-ray analysis with the aim of comparing their conformations with those of known 
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analogous peptides. For example, Toniolo and coworkers described the crystal structures of the tripeptides Z-(S)-(αMe)Phe-Aib-Aib-OH and 
Z-Aib-(R)-(αMe)Phe-Aib-OtBu, the tetrapeptide Z-Aib-Aib-(R)-(αMe)Phe-Aib-OtBu, and the pentapeptide 4-BrC6H4-CO-Aib-Aib-(R,S)-
(αMe)Phe-Aib-Aib-OtBu and concluded that (αMe)Phe strongly induces helical conformations.[55–59, 73] But in contrast to proteinogenic 
amino acids, the configuration of which determines the sense of the helical screw of the peptide (L(S)-configuration → right-handed helix 
(P)), this is not the case for (αMe)Phe, and Crisma and Toniolo summarized ‘the reverse relationship between (αMe)Phe chirality and helix 
screw sense (L → left handed (M) and D → right handed (P)) prevails in the ratio 67% : 33%’.[73] Whereas the tetrapeptide 4-BrC6H4-CO-
[(R)-(αMe)Phe]4-OtBu and the tripeptide 4-BrC6H4-CO-[(R)(αMe)Phe]3-OH crystallize as right-handed helices,[73] the dipeptide amide 4-
BrC6H4-CO-[(R)-(αMe)Phe]2-NHMe forms a left-handed β-turn of type III’.[57] In the case of the pentapeptide 4-BrC6H4-CO-(R)-(αMe)Phe-
Aib-Aib-(R)-(αMe)Phe-Aib-OtBu containing two (R)-(αMe)Phe units, the molecules in the crystalline state form right-handed 310-helical 
structures stabilized by three intramolecular hydrogen bonds.[55] 
The crystals of the tetrapeptide (S,S,R)-12 are enantiomerically pure, but the absolute configuration of the molecule has not been 
determined by crystallographic methods. The enantiomer used in the refinement was based on the known (5S,14R)-configuration of the 
molecule. Based on this assumption, the configuration at C(11) is S. The molecule forms a 310-helix, which is held in place by two 
intramolecular hydrogen bonds (Fig. 3, Table 1). N(7)–H and N(10)–H interact with the carbamate O(21)- and the amide O(3)-atom, 
respectively, forming formal ten-membered rings (β-turns, graph set motif[72] S(10)). The other two amide NH groups are involved in 
intermolecular hydrogen bonds: N(1)–H forms a H-bond with the amide O(12’) at the opposite end of a neighboring molecule and N(4)–H 
forms a weak H-bond with the same O(12’). These two intermolecular interactions link the molecules into extended chains, which run 
parallel to the [001] direction and can be described by the graph set motifs C(14) and C(11), respectively. The conformation of the 
tetrapeptide derivative is characterized by two consecutive β-turns of type III, i.e. it corresponds with a right-handed 310-helical structure 
with torsion angles φ1–3 and ψ1–3 (Table 2) in accordance with those of an ideal 310-helix (φ = –60°, ψ = –30°). This result is remarkable in 
comparison with the pentapeptide 4-BrC6H4-CO-(R)-(αMe)Phe-Aib-Aib-(R)-(αMe)Phe-Aib-OtBu described by Toniolo et al.[55] Although 
the configurations of the two incorporated (αMe)Phe units are opposite, right-handed helices are formed in both cases. It is also worth 
mentioning that in the previously described pentapeptide Z-Gly-Aib-(RS)-(αMe)Phe-Aib-Gly-OMe the molecule containing (S)-(αMe)Phe 




Figure 3. ORTEP Plot[71] of the molecular structure of the tetrapeptide derivative (S,S,R)-12 (50% probability ellipsoids; arbitrary numbering 
of atoms; H-atoms bonded to C-atoms have been omitted for clarity) 
 
Table 1. Intramolecular hydrogen bonds of tetrapeptide derivatives (S,S,R)-12, (S,R,R)-12, (S,R,R)-13, (S,S)-16, and (S,R)-17 (atom 
numbering refers to Figs. 3 – 7) 
Compound N(7)–H....O(21)/O(22) 
N….O (Å)    N–H….O (°) 
N(57)–H....O(70)[a]  
N….O (Å)    N–H….O (°) 
N(10)–H....O(3)  
N….O (Å)    N–H….O (°) 
N(60)–H....O(53)[a]  





3.063(4)      164(3)    
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3.198(8)      148 
 
3.055(7)      169 
 
 







3.159(10)    166 
  






2.917(4)      165(4) 
 
 
3.045(4)      162(5) 
 
2.945(4)      164(3)  
 
 




3.030(7)      148 
 
 
2.961(6)      151 
 
3.018(6)      141 
 
 
2.935(6)      151 
 
                         
[a] In those structures with two symmetry-independent molecules 
 














































































Also the crystals of (S,R,R)-12 are enantiomerically pure; the enantiomer used in the refinement was based on the known S-
configuration of C(5). Therefore, the configurations of C(11) and C(14) are both R. The asymmetric unit contains two symmetry-independent 
molecules of the peptide plus two AcOEt molecules.  Peptide molecule B exhibits disorder of the terminal methylbenzyl group and of the 
terminal O-benzyl ring.  The solvent molecules are also disordered.  The torsion angles (Table 2) show that the backbones of the two 
independent peptide molecules have virtually identical conformations and the same absolute configuration.  The main differences between 
the molecules are small twists in the orientations of some of the phenyl groups. Both molecules form helical structures (Figure 4, molecule 
A) similar to (S,S,R)-12,but the first β-turn of type III is followed by a type I β-turn (φ3 ≈ –90°, ψ3 ≈ 0°). The torsion angles φ4 and ψ4 of the 
last amino acid, (R)-(αMe)Phe, are inverted compared with those of (S,S,R)-12. In each molecule, two intramolecular H-bonds (N(7)–
H….O(21) and N(10)–H….O(3), graph set motif S(10), Table 1) are formed in analogy to (S,S,R)-12. Intermolecular H-bonds between N(4)–H 
and the amide O(12’) atom at the opposite end of a neighboring molecule A link the molecules of type A into extended chains, which run 
parallel to the [100] direction (graph set motif C(11)). Remarkably, the carbamate N(1)–H does not form any hydrogen bond. Molecules B 
exhibit the same pattern of interactions as molecules A, except that the carbamate N(51)–H forms an intermolecular H-bond with O(62’) of a 
Chem. Biodiversity 
8 
neighboring type B molecule, while N(54)–H is not involved in any hydrogen bonds. Once again, the intermolecular interactions form 
extended chains, which run parallel to the [100] direction, but in this case the graph set motif is C(14). 
 
 
a)                        b) 
                  
 
Figure 4. ORTEP Plots[71] of the molecular structures of the tetrapeptide derivative (S,R,R)-12 (a) molecule A and b) one conformation of 
molecule B; 50% probability ellipsoids; arbitrary numbering of atoms; H-atoms bonded to C-atoms have been omitted for clarity) 
 
In contrast to the Z-protected tetrapeptide (S,R,R)-12, the derivative (S,R,R)-13 with  a terminal 4-bromobenzoyl group exists as a 
uniform conformer. The compound in the crystal is enantiomerically pure and its absolute configuration (5S,11R,14R) has been determined 
independently by the diffraction experiment. The asymmetric unit contains one peptide molecule (Figure 5) plus one disordered AcOEt 
molecule. The peptide molecules form helices, which are held in place by two intramolecular H-bonds analogous to (S,S,R)-12 and (S,R,R)-
12 (N(7)–H….O(21) and N(10)–H….O(3), Table 1; graph set motif S(10)). The torsion angles φ1–3 and ψ1–3 are again very similar to those of 
(S,S,R)-12 and φ4 and ψ4 are inverted, analogous to the case of (S,R,R)-12 (Table 2). In contrast to (S,R,R)-12, the values of φ3 and ψ3 are 
close to the ideal values of a β-turn type III. Therefore, the peptide backbone of (S,R,R)-13 forms two consecutive β-turns of type III, i.e. a 
310-helical conformation. The comparison of (S,R,R)-12 and (S,R,R)-13 shows that the N-terminal protecting group (Z or 4-Br-C6H4CO) has 
some influence on the peptide-conformation. Similar to molecule B of (S,R,R)-12, N(1)–H forms an intermolecular H-bond with the amide 
O(12’) atom of a neighboring molecule leading to extended chains, which run parallel to the [010] direction (graph set motif C(14)). N(4)–H 




Figure 5. ORTEP Plot[71] of the molecular structure of the tetrapeptide derivative (S,R,R)-13 (50% probability ellipsoids; arbitrary numbering 




The space group of the crystals of tetrapeptide (S,S)-16 also permits the compound to be enantiomerically pure, but the absolute 
configuration of the molecule has not been determined. The enantiomer used in the refinement was based on the known S-configuration of 
C(5). There are two symmetry-independent peptide molecules in the asymmetric unit plus one water molecule with full site occupancy and a 
second water molecule, which seems to be present only at ca. 30% of its sites. Both peptide molecules A and B (Figure 6) form left-handed 
helices, which are held in place by two intramolecular H-bonds, as in the previous cases (N(7)–H….O(20), N(10)–H….O(3) and N(57)–
H….O(70), N(60)–H….O(53), respectively; Table 1; graph set motif S(10)). The two independent peptide molecules have virtually identical 
backbone conformations and the same absolute configuration. The torsion angles (Table 2) correspond with two consecutive β-turns of type 
III’. Again it is worth mentioning that left-handed helical structures are formed although two S-configured (αMe)Phe units are included in 
positions 2 and 3, whereas in (S,S,R)-12, with two (S)-(αMe)Phe units in positions 2 and 4, a right-handed helix is exhibited. 
Again, N(1)–H forms an intermolecular H-bond with the amide O(12’) atom of a neighboring molecule A. These interactions link 
the molecules of type A into extended chains, which run parallel to the [001] direction and can be described by a graph set motif of C(14). 
Molecules B exhibit exactly the same pattern of interactions as molecule A, except that the chains run parallel to the [100] direction. N(4)–H 
donates a H-bond to the partial occupancy water molecule while O(12) probably accepts a H-bond from a different water molecule. Thus this 
water molecule is part of the linking process in the chains of molecule A. Similarly, N(54)–H of molecule B donates to the full occupancy 
water molecule, but this water molecule appears to be a H-bond donor to O(71) as well as to O(59) of an adjacent molecule. In this way, this 





Figure 6. ORTEP Plots[71] of the molecular structures of the two symmetry-independent molecules of tetrapeptide derivative (S,S)-16 (50% 
probability ellipsoids; arbitrary numbering of atoms; H-atoms bonded to C-atoms have been omitted for clarity) 
 
Finally, crystal structure analysis of the tetrapeptide derivative (S,R)-17 shows that the compound is enantiomerically pure and the 
absolute configuration has been determined independently by the diffraction experiment. The molecule has the (5S,8R)-configuration. The 
asymmetric unit contains two independent peptide molecules plus one ordered and one disordered AcOEt molecule. As in the other cases, the 
peptide molecules form helices of type 310 (Figure 7), i.e. two consecutive β-turns of type III/III’ with two intramolecular hydrogen bonds in 
each case (N(7)–H….O(20), N(10)–H….O(3) and N(57)–H….O(70), N(60)–H….O(53), respectively; Table 1, graph set motif S(10)). The 
torsion angles (Table 2) show that the backbones of the two independent molecules with the same absolute configuration have almost perfect 
mirror image conformations. Whereas in molecule A two β-turns of type III’ form a left-handed helical structure, two β-turns of type III 












         
 
Figure 7. ORTEP Plots[71] of the molecular structures of the two symmetry-independent molecules of tetrapeptide derivative (S,R)-17 (50% 
probability ellipsoids; arbitrary numbering of atoms; H-atoms bonded to C-atoms have been omitted for clarity) 
 
The pattern of the intermolecular hydrogen bonds is again similar to that in the peptides describe above. N(1)–H of molecule A 
forms a H-bond with the amide O(12’) atom of a neighboring molecule A, thereby linking the molecules into extended chains, which run 
parallel to the [001] direction. N(4)–H interacts with the O-atom of the disordered AcOEt molecule. The same H-bond pattern is observed for 




With the presented synthesis of the 3-amino-2H-azirines (R,R)- and (S,R)-2a, useful new synthons for enantiomerically pure (αMe)Phe are 
available. It has been shown that these building blocks are more reactive than the earlier described derivatives (S,S)- and (R,S)-3,[68] which is 
of importance for their application in peptide synthesis via the ‘azirine/oxazolone method’. Even more reactive is the racemic (αMe)Phe 
synthon rac-14 bearing a dimethylamino group at C(3). Obviously, the type and bulkiness of the N-substituents play a significant role. By 
using these three (αMe)Phe synthons in the ‘azirine/oxazolone method’, three types of N-protected tetrapeptide amides containing two 
(αMe)Phe and two Aib units were prepared successfully. 
The solid-state conformations of five of these tetrapeptides have been determined by X-ray diffraction analysis. As expected for 
peptides containing α,α-disubstituted α-amino acids, all peptides adopt helical conformations held in place by two intramolecular hydrogen 
bonds to form two consecutive β-turns. Furthermore, the statement of Crisma and Toniolo[73] that, in contrast to proteinogenic amino acids, 
the configuration of (αMe)Phe does not determine the screw sense of the helix unambiguously has been confirmed. Thus, the tetrapeptide 
(S,S,R)-12 containing two S-configured (αMe)Phe units forms a right-handed 310-helix very similar to that of 4-BrC6H4-CO-(R)-(αMe)Phe-
Aib-Aib-(R)-(αMe)Phe-Aib-OtBu with two R-configured (αMe)Phe units.[55] Also (S,R,R)-12 and (S,R,R)-13, which contain one S- and one 
R-configured (αMe)Phe, adopt a right-handed helical structure, but the C-terminal (αMe)Phe unit is twisted. Furthermore, the kind of the N-
terminal protecting group, Z or 4-BrC6H4-CO, has little influence on the backbone conformation. Surprisingly, peptide (S,S)-16, which 
possesses two (S)-(αMe)Phe inserted in positions 2 and 3, exists in the crystal as left-handed 310-helices, in contrast to (S,S,R)-12 with the 
two (S)-(αMe)Phe residues in positions 2 and 4. Obviously, the position of (αMe)Phe in the peptide sequence also plays a crucial role in the 
determination of the sense of the helical screw. Even more astonishing is the presence of a 1:1 mixture of left- and right-handed 310-helices in 






See refs. [66, 68, 74] The used 3-amino-2H-azirines (S,S)- and (R,S)-3 ((S,S)- and (R,S)-1-(2-benzyl-2-methyl-2H-azirin-3-yl)-2-(1-methoxy-1-
methylethyl)pyrrolidine)[68], 9 (2,2,N-trimethyl-N-phenyl-3-amino-2H-azirine),[61,62] and rac-14 ((R/S)-2-benzyl-2,N,N-trimethyl-3-amino-2H-
azirine),[70] as well as (R)-N-methyl-N-(1-phenylethyl)propanamide ((R)-4),[66] were prepared previously. All other chemicals were 
commercially available. If not otherwise indicated, IR spectra in KBr, 1H- and 13C-NMR spectra in CDCl3 at 300 and 75 MHz, respectively. 
 
General Procedure 1 (GP 1, Coupling with 2H-azirin-3-amines). To a solution of an N-protected amino acid or N-protected peptide in 
CH2Cl2 at 0°, a solution of the corresponding 2H-azirin-3-amine in CH2Cl2 was added and the mixture was stirred at r.t. for several h. After 
completion of the reaction, the solvent was evaporated and the product was purified chromatographically (SiO2, AcOEt/hexane) or by 
crystallization. In some cases, the product was obtained as an amorphous solid. 
 
General Procedure 2 (GP 2, Selective hydrolysis of peptide amides). To a solution of the peptide amide in THF at r.t., the same volume of 
6N HCl was added and the mixture stirred at r.t. until the starting material disappeared. Then, CH2Cl2 was added and the mixture was 
extracted with 1N HCl and saturated aqueous NaCl solution. The organic layer was dried (MgSO4) and the solvent evaporated. The product 
was precipitated or purified chromatographically (SiO2). 
 
Synthesis of 2-benzyl-2-methyl-3-[N-methyl-N-(1-phenylethyl)amino]-2H-azirine ((R,R)- and (S,R)-2a 
(R)-2-Benzyl-N-methyl-N-(1-phenylethyl)propanamide ((R,R)/(S,R)-5). Analogous to ref.[74], to a solution of 12.9 g (67.4 mmol) of (R)-N-
methyl-N-(1-phenylethyl)propanamid ((R)-4) in 100 mL of THF was added 58 mL of a 1.5N solution of LDA at 0 °C. Then, 11.8 g (69.0 
mmol) of benzylbromide were added and the mixture was stirred at 0 °C for 2 h. After addition of aqueous 2N HCl, extraction with Et2O, 
and column chromatography (CC, SiO2, hexane/AcOEt 1:1), 18.2 g (96%) of a ca. 2:1 mixture of two diastereomers of 2a were obtained. IR 
(neat): 3020m, 2965s, 2925m, 1635s, 1490m, 1450m, 1400m, 1080m, 740m, 730m, 700s. 1H-NMR (2 diastereomers + rotamers): 7.35–7.15, 
6.95–6.9, 6.75–6.7 (3m, 10 arom. H), 6.1–5.9, 5.15–5.05, 5.0–4.95 (3m, NCHMePh), 3.2–3.0, 2.70 (m and dd, J = 11.8, 4.5, PhCH2, 
MeCHCO), 2.59, 2.56, 2.47, 2.39, 2.34 (5s, NMe), 1.55, 1.42, 1.29, 1.25, 1.21, 1.09 (6d, J = ca. 7, 2 Me). 13C-NMR: 175.8, 175.7 (2s, CO), 
140.8, 140.3, 140.2 (3s, 2 arom. C), 129.2,129.0, 128.6, 128.3, 128.2, 128.2, 127.1, 126.8, 126.3, 126.2, 126.1, 126.1, 125.2 (14d, 10 arom. 
CH), 54.4, 54.2, 50.0 (3d, NCHMePh), 41.2, 40.6, 40.4 (3t, PhCH2), 38.6, 38.4 (2q, NMe), 29.4, 29.1, 28.1 (3d, MeCHCO), 18.7, 17.8, 17.2 
(3q, NCHMePh), 15.5, 15.2 (2q, MeCHCO). EI-MS: 281 (97, M+.). 266 (14), 162 (29), 120 (51, [HNCHMePh]+), 119 (35), 118 (13), 105 (96, 
[CHMePh]+), 103 (12), 91 (100, [C7H7]+), 77 (25). Anal. calc. for C19H23NO (281.40): C 81.10, H 8.24, N 4.98; found: C 81.41, H 8.46, N 
4.97. 
 
(R)-2-Benzyl-N-methyl-N-(1-phenylethyl)propanethioamide ((R,R)/(S,R)-6). A solution of 18.1 g (64.3 mmol) (R,R)/(S,R)-5 and 14.3 g 
Lawesson reagent (LR) in 100 mL of toluene was heated to 100 °C for 18 h. Evaporation of the solvent and chromatographic workup (CC, 
SiO2, hexane/AcOEt 10:1) gave 16.0 g (84%) of 6 as a mixture of diastereoisomers. IR (CHCl3): 3060w, 2970s, 2925s, 1600w, 1490s, 1480s, 
1450s, 1410s, 1380m, 1310m, 1260s, 1090s, 1060s, 990m, 970m, 700s, 660m. CI-MS: 298 ([M+H]+). Anal. calc. for C19H23NS (297.46): C 
76.72, H 7.79, N 4.71, S 10.78; found: C 76.57, H 7.76, N 4.60, S 10.52. 
A small amount of the mixture was separated by TLC (SiO2, hexane/AcOEt 10:1). Diastereomer 6a (Rf = 0.25): M.p. 101–103 °C. [α]D 
+335.4 (CHCl3, c = 0.999). 1H-NMR (2 rotamers ca. 2:1): 7.35–7.15 (m, 10 arom. H), 6.7–6.65, 5.65–5.55 (2m, NCHMePh), 3.65–3.6, 3.45–
3.2 (2m 1 H of PhCH2 and MeCHCO), 2.95–2.8 (m, 1 H of PhCH2), 3.02, 2.54 (2s, NMe), 1.61, 1.36, 1.33, 1.31 (4d, J = ca. 7, 2 Me). 13C-
NMR: 209.7, 209.2 (2s, CS), 140.2, 139.9, 139.2, 138.6 (4s, 2 arom. C), 129.4, 129.2, 128.7, 128.5, 128.4, 128.2, 127.7, 127.5, 126.8, 126.4, 
126.3, 126.2 (12d, 10 arom. CH), 58.1 (d NCHMePh), 44.6 (q, NMe), 44.2 (t, PhCH2), 37.8, 33.3 (2d, MeCHCO), 22.6, 21.7, 17.5, 14.0 (4q, 
2 Me). 
Diastereomer 6b (Rf = 0.3): [α]D +107.8 (CHCl3, c = 1.009). 1H-NMR (2 rotamers ca. 3:1): 7.35–7.05, 6.85–6.8 (m, 10 arom. H and 0.75 H 
of NCHMePh), 5.5–5.45 (m, 0.25 H of NCHMePh), 3.65–3.6, 3.45–3.5, 3.35–3.25 (3m, 1 H of PhCH2 and MeCHCO), 2.95–2.8 (m, 1 H of 
PhCH2), 3.04, 2.66 (2s, NMe), 1.48, 1.43, 1.34, 1.10 (4d, J = ca. 7, 2 Me). 13C-NMR: 209.5 (s, CS), 140.2, 139.9, 139.1, 138.8 (4s, 2 arom. 
C), 129.4, 129.2, 128.9,128.5, 128.3, 127.8, 127.3, 126.8, 126.4, 126.3, 126.2 (11d, 10 arom. CH), 58.4 (d, NCHMePh), 44.8, 43.9 (2t, 
PhCH2), 44.6, 44.6 (2q, NMe), 37.7, 33.8 (2d, MeCHCO), 23.0, 21.8, 17.0, 14.1 (4q, 2 Me). 
 
(R,R)- and (S,R)-2-Benzyl-2-methyl-3-(N-methyl-N-(1-phenylethyl)amino-2H-azirine ((R,R)- and (S,R)-2a). To a solution of 6.45 g (21.7 
mmol) (R,R)/(S,R)-6 in 25 mL of CH2Cl2 and 3 drops of DMF were added 12 mL of a 2N phosgene (COCl2) solution in toluene at 0 °C. The 
mixture was stirred at 0 °C for 1 h. Then, the solvent was evaporated, the residue dissolved in 30 mL of THF and 2.43 g of 1,4-
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diazabicyclo[2.2.2]octane (DABCO) were added at 0 °C. After 30 min, the mixture was filtered and the filtrate was treated with 3 g (46.1 
mmol) NaN3 at r.t. over night. After filtration via Celite and extraction with CH2Cl2 and saturated aqueous NaHCO3 solution, the solvent was 
evaporated and the residue purified by chromatography (CC followed by MPLC, SiO2, hexane/AcOEt 1:1) to give 4.85 g (80%) of 
(R,R)/(S,R)-2a as a ca. 1:1 mixture of diastereomers. IR (neat): 3080w, 3060w, 3020w, 2965m, 2930m, 2900m, 1760s, 1600w, 1445m, 
1370m, 1240m, 1075m, 760w, 700s. CI-MS: 279 (100, [M+1]+), 277 (18, [M–1]+), 173 (53). 
The diastereomers were separated by TLC (SiO2, hexane/AcOEt 1:1) and obtained in nearly equal amounts. (S,R)-2a (Rf = 0.35)3): [α]D 
+1.18 (CHCl3, c = 0.997). 1H-NMR ((D6)DMSO, 363 K): 7.4–7.15 (m, 10 arom. H), 4.64 (q, J = ca. 7, NCHMePh), 2.89, 2.81 (AB, J = 14.3, 
PhCH2), 2.67 (s, NMe), 1.48 (d, J = ca. 7, NCHMePh), 1.22 (s, Me). 13C-NMR (75 MHz, CDCl3): 165.9 (s, C(3)), 141.4, 139.0 (2s, 2 arom. 
C), 129.8, 128.8, 128.1, 127.6, 127.0, 126.2 (6d, 10 arom. CH), 58.5 (d, NCHMePh), 44.7 (t, PhCH2), 42.8 (q, NMe), 33.0 (s, C(2)), 23.7 (q, 
NCHMePh), 18.2 (q, Me). Anal. calc. for C19H22N2 (278.40): C 82.09, H 7.97, N 10.06; found: C 81.88, H 7.90, N 10.06. 
(R,R)-2a (Rr = 0.3): [α]D +78.75 (CHCl3, c = 1.021). 1H-NMR ((D6)DMSO, 363 K): 7.35–7.15 (m, 10 arom. H), 4.60 (q, J = ca. 7, 
NCHMePh), 2.82 (s, PhCH2), 2.67 (s, NMe), 1.48 (d, J = ca. 7, NCHMePh), 1.23 (s, Me). 13C-NMR (75 MHz, CDCl3): 165.8 (s, C(3)), 141.4, 
139.1 (2s, 2 arom. C), 129.8, 128.8, 128.2, 127.6, 126.9, 126.2 (6d, 10 arom. CH), 58.6 (d, NCHMePh), 44.8 (t, PhCH2), 43.1 (q, NMe), 32.4 
(s, C(2)), 23.9 (q, NCHMePh), 18.0 (q, Me). 
 
3) X-ray crystal structure determinations of the peptides prepared using the diastereomer with higher Rf value showed that the less polar 
isomer has S,R-configuration. 
 
Synthesis of tetrapeptide amides (S,S,R)-12, (S,R,R)-12, and (S,R,R)-13 with alternating Aib and (αMe)Phe units 
(S,S)-N-(Benzyloxycarbonyl)-N’-{1-benzyl-1-methyl-2-[2-(1-methoxy-1-methylethyl)pyrrolidin-1-yl]-2-oxoethyl}aminoisobutanamide ((S,S)-
Z-Aib-(αMe)Phe-[2-(1-methoxy-1-methylethyl)pyrrolidid], (S,S)-7). To a solution of 119 mg (0.5 mmol) Z-Aib-OH in 3 mL of CH2Cl2 were 
added 158 mg (0.55 mmol) of azirine (S,S)-3 dissolved in 2 mL of CH2Cl2 and the mixture was stirred at r.t. for 4 d. Evaporation of the 
solvent and chromatographic workup (CC, SiO2, hexane/AcOEt 1:1) gave 220 mg (84%) of (S,S)-7. M.p. 151–152 °C. [α]D –14.9 (CHCl3, c 
= 0.525). IR: 3360s, 3300s, 2970s, 2940m, 1715s, 1660s, 1610s, 1500s, 1430s, 1395m, 1325s, 1220m, 1200m, 1080s, 1055s, 700s, 655m. 
1H-NMR: 7.54 (s, NH), 7.35–7.3, 7.25–7.15 (2m, 10 arom. H), 5.46 (br s, NH), 5.07, 5.03 (AB, J = 14.4, PhCH2), 3.4–3.35 (m, 1 H), 3.17 (s, 
MeO), 2.0–1.9 (m, 2 H), 1.65 (br s, 2 H), 1.57, 1.47, 1.13, 0.98 (4s, 5 Me). 13C-NMR: 172.3, 171.4 (2s, 2 amide CO), 154.8 (s, OCONH), 
136.3, 130.1 (2s, 2 arom. C), 130.1, 128.4, 128.1, 128.0, 126.8 (5d, 10 arom. CH), 78.6 (s, Me2COMe), 66.4 (t, PhCH2O), 65.0 (d, NCH), 
61.0, 57.0 (2s, NCMeCH2Ph and NCMe2), 49.0 (q, MeO), 48.3, 41.3 (2t, 2 CH2), 25.6 (q, Me), 25.3 (t, CH2), 25.0 (q, Me), 23.8 (t, CH2), 23.0, 
22.7, 22.1 (3q, 3 Me). CI-MS: 524 ([M+1]+). Anal. calc. for C30H41N3O5 (523.68): C 68.81, H 7.89, N 8.02; found: C 68.87, H 7.83, N 8.03. 
  
Z-Aib-(S)-(αMe)Phe-OH ((S)-8). According to GP 2, a solution of 1.00 g (1.91 mmol) (S,S)-7 in 15 mL of THF was treated with 15 mL of 
6N HCl at 40 °C overnight. Chromatography (CC, SiO2, AcOEt) and precipitation of the product by addition of Et2O/hexane yielded 0.723 g 
(ca. 92%) of (S)-8, contaminated with butane-1,4-diol. TLC (SiO2, AcOEt) led to pure (S)-8. [α]D +24.95 (CHCl3, c = 0.489). IR: 3320s, 
2980m, 2940m, 1725s, 1660s, 1540s, 1500m, 1460s, 1420m, 1340s, 1200m, 1130s, 700s, 640m. 1H-NMR: 7.35–7.3, 7.3–7.20, 7.15–7.1 (3m, 
10 arom. H), 6.84 (s, NH), 5.44 (br s, NH), 5.02 (s, PhCH2O), 3.36, 3.29 (AB, J = 13.7, PhCH2), 1.57, 1.45 (2s, 3 Me). 13C-NMR: 176.9, 
174.1 (2s, 2 CO), 155.4 (s, OCONH), 136.0, 135.8 (2s, 2 arom. C), 130.2, 128.5, 128.2, 128.0, 127.0 (5d, 10 arom. CH), 67.0 (t, PhCH2O), 
60.6, 57.1 (2s, NCMeCH2Ph and NCMe2), 41.5 (t, PhCH2), 25.5, 25.2, 22.9 (3q, 3 Me). ESI-MS: 399 ([M+1]+). 
 
Z-Aib-(S)-(αMe)Phe-Aib-N(Me)Ph ((S)-10). According to GP 1, a mixture of 405 mg (1.02 mmol) (S)-8 and 182 mg (1.05 mmol) azirine 9 
in 5 mL of CH2Cl2 was stirred for 1 h at 0 °C. Chromatographic workup (CC, SiO2, CH2Cl2/MeOH 19:1) gave 537 mg (92%) of (S)-10 as 
foam, which was purified by TLC (SiO2, CH2Cl2/MeOH 19:1). IR: 3320s (br), 3060m, 3020m, 2980m, 2930m, 1705s, 1660s, 1640s, 1590m, 
1525s, 1495s, 1450s, 1390m, 1360s, 1265s, 1195m, 1170m, 1090s, 1070s, 700s. 1N-NMR: 7.52 (s, NH), 7.4–7.25, 7.2–7.1 (2m, 15 arom. H), 
6.43 (br s, NH), 5.43 (br s, NH), 5.06, 4.89 (AB, J = 12.3, PhCH2O), 3.44, 3.13 (AB, J = 13.9, PhCH2), 3.35 (s NMe), 1.47, 1.46, 1.45, 1.44, 
1.38 (5s, 5 Me). 13C-NMR: 173.6, 172.9, 172.2 (3s, 3 amide CO), 155.4 (s, OCONH), 145.3, 136.3, 136.1 (3s, 3 arom. C), 130.6, 129.2, 
128.6, 128.4, 128.2, 128.0, 127.8, 127.2, 126.9 (9d, 15 arom. CH), 66.9 (t, PhCH2O), 60.2, 58.0, 57.4 (3s, 3 C(α)), 41.8 (t, PhCH2), 40.7 (q, 




Z-Aib-(S)-(αMe)Phe-Aib-OH ((S)-11). According to GP 2, a solution of 353 mg (0.62 mmol) (S)-10 in 2 mL of THF was treated with 2 mL 
of 6N HCl at 40 °C for 2 h. After extraction and evaporation of the solvent, 270 mg (91%) of (S)-11 was obtained as foam. IR: 3320s (br), 
3060m, 3020m, 2980m, 2930m, 17o5s, 1660s, 1530s (br), 1455s, 1380s, 1365m, 1320m, 1265s, 1175m, 1090m, 1075m, 745m, 700s. 1H-
NMR: 7.39 (s, NH), 7.35–7.3, 7.3–7.2, 7.1–7.05 (3m, 10 arom. H), 6.68 (br s, NH), 5.77 (br s, NH),5.03, 4.88 (AB, J = 12.2, PhCH2O), 3.26, 
2.99 (AB, J = 14.2, PhCH2), 1.53, 1.49, 1.46, 1.41, 1.37 (5s, 5 Me). 13C-NMR: 175.7, 174.5, 173.7 (3s, 3 CO), 155.8 (s, OCONH), 135.9, 
135.6 (2s, 2 arom. C), 130.6, 128.6, 128.5, 128.3, 128.1, 127.1 (6d, 10 arom. CH), 67.9 (s, C(α)), 67.3 (t, PhCH2O), 59.7, 57.5 (2s, 2 C(α)), 
42.3 (t, PhCH2), 25.6, 25.3, 25.1, 24.8, 23.4 (5q, 5 Me). ESI-MS: 506 ([M+Na]+), 484 ([M+1]+). 
 
Z-Aib-(S)-(αMe)Phe-Aib-(S)-(αMe)Phe-N(Me)PhEt ((S,S,R)-12). According to GP 1, a mixture of 90 mg (0.186 mmol) (S)-11 and 60 mg 
(0.216 mmol) azirine (S,R)-2a in 2.5 mL of CHCl3 was stirred at r.t. for 4 d. CC (SiO2, CH2Cl2/MeOH 95:1) yielded 125 mg (88%) of 
(S,S,R)-12). M.p. 233–235 °C (AcOEt/hexane). [α]D –24.2 (CHCl3, c = 0.124). IR: 3390m, 3250s, 3200s, 3060m, 3025m, 2980m, 2930m, 
1705s, 1680s, 1660s, 1530s (br), 1450m, 1440m, 1270s, 1235m, 1185m, 1085m, 745m, 700s. 1H-NMR: 7.35–7.1, 6.95–6.9 (2m, 20 arom. H 
and 1 NH), 6.17 (s, NH), 6.08 (q, J = 6.8, NCHMePh), 4.97 (s, NH), 4.93, 4.77 (AB, J = 12.2, PhCH2O), 3.44, 3.36 (AB, J =13.8 PhCH2), 
3.18, 2.85 (AB, J = 14, PhCH2), 2.73 (s, NMe), 1.41 (d, J = 7, NCHMePh), 1.56, 1.47, 1.38, 1.23, 1.15, 1.07 (6s. 6 Me).4) ESI-MS: 785 
([M+Na]+). Suitable crystals for the X-ray crystal structure determination were obtained from AcOEt/hexane. 
 
4) The solubility of the (S,S,R)-12 was very low so that no reasonable 13C-NMR spectrum was obtained. 
 
Z-Aib-(S)-(αMe)Phe-Aib-(R)-(αMe)Phe-N(Me)PhEt ((S,R,R)-12). According to GP 1, a mixture of 90 mg (0.186 mmol) (S)-11 and 60 mg 
(0.216 mmol) azirine (R,R)-2a in 2.5 mL of CHCl3 was stirred at r.t. for 4 d. CC (SiO2, CH2Cl2/MeOH 95:1) yielded 131 mg (92%) of 
(S,R,R)-12). M.p. 170–172 °C (AcOEt/petroleum ether). [α]D –6.8 (CHCl3, c = 0.133). IR: 3320s, 3220m, 3060m, 3025m, 2980m, 2935m, 
1725s, 1685s, 1660s, 1620s, 1540s, 1515s, 1455s, 1400m, 1380m, 1265s, 1240m, 1185m, 1080s, 745m, 700s. 1H-NMR: 7.3–7.0, 7.0–6.9 
(2m, 20 arom. H), 6.82, 6.41 (2s, 2 NH), 6.05 (q, J = 6.8, NCHMePh), 5.31 (s, NH), 4.88, 4.68 (AB, J = 12.2, PhCH2O), 3.36 (br s, PhCH2), 
3.04, 2.76 (AB, J = 14, PhCH2), 2.70 (s, NMe), 1.41 (d, J = 7, NCHMePh), 1.57, 1.47, 1.31, 1.29, 1.23, 1.00 (6s, 6 Me). 13C-NMR: 173.8, 
173.4, 171.9, 171.7 (4s, 4 CO), 155.4 (s, OCONH), 141.3, 137.2, 135.7, 135.3 (4s, 4 arom. C), 131.1, 130.3, 128.6, 128.5, 128.5, 128.3, 
128.0, 127.6, 127.1, 126.6, 126.2 (11d, 20 arom. CH), 67.2 (t, PhCH2O), 60.2, 59,5, 57.7, 57.3 (4s, 4 C(α)),  51.9 (d, NCHMePh), 43.6, 42.6 
(2t, 2 PhCH2), 30.5 (q, NMe), 26.9, 25.9, 24.8, 24.4, 23.2, 23.0, 14.8 (7q, 7Me). ESI-MS: 785 ([M+Na]+). Suitable crystals for the X-ray 
crystal structure determination were obtained from AcOEt/hexane. 
 
4-BrC6H4CO-Aib-(S)-(αMe)Phe-Aib-(R)-(αMe)Phe-N(Me)PhEt ((S,R,R)-13). To a solution of (S,R,R)-12 (150 mg, 0.197 mmol) in 5 mL of 
MeOH were added 70 mg Pd/C (10%) and 60 mg ammonium formate (HCO2NH4) and the mixture was heated to reflux for 1 h. The 
suspension was filtered through Celite, the solvent of the filtrate was evaporated, the residue was dissolved in CH2Cl2 and extracted with 1N 
NaOH. The solvent of the organic phase was evaporated, the residue dissolved in AcOEt (2 mL), and Et3N (0.2 mL) and 50 mg 4-
bromobenzoyl chloride were added. The mixture was stirred at r.t. for 1 h and then washed with 1N HCl. Crystallization was achieved by 
addition of petroleum ether, yielding 144 mg (90%) of (S,R,R)-13, which was purified by TLC (SiO2, CH2Cl2/MeOH 95:1). M.p. 200–202 °C 
(AcOEt/petroleum ether). [α]D +22 (CHCl3, c = 0.1). IR: 3405m, 3320s (br), 3220m, 3060w, 3025w, 2990m, 2940m, 1735s, 1670s (br), 
1625s, 1590s, 1530s (br), 1494s, 1485s, 1455s, 1395m, 1380s, 1370s, 1305m, 1280m, 1240s, 1220m, 1185m, 1115m, 1085s, 1070m, 1050m, 
1030m, 1010m, 780m, 760m, 745m, 735m, 700s. 1H-NMR: 7.57, 7.49 (2d, J = 13.6, 4 arom. H), 7.42 (s, NH), 7.25–6.85 (m, 15 arom. H), 
6.31 (s, NH), 5.96 (q, J = 7, NCHMePh), 3.36, 3.30 (AB, J = 14, PhCH2), 3.04, 2.72 (AB, J = 14, PhCH2), 2.71 (s, NMe), 1.60, 1.48 (2s, 2 
Me), 1.4–1.35 (m, NCHMePh and 1 Me), 1.34, 1.29, 1.12 (3s, 3 Me). ESI-MS: 834, 832 ([M+Na]+). Suitable crystals for the X-ray crystal 
structure determination were obtained from AcOEt/petroleum ether. 
 
Synthesis of tetrapeptide amides (S,S)-16, (S,R)-16, and (S,R)-17 with accumulated (αMe)Phe units 
Z-Aib-(S)-(αMe)Phe-(S)-(αMe)Phe-NMe2 ((S,S)-15) and Z-Aib-(S)-(αMe)Phe-(R)-(αMe)Phe-NMe2 ((S,R)-15). According to GP 1, a 
mixture of 399 mg (1.00 mmol) (S)-8 in10mL of CH2Cl2 and 200 mg (1.06 mmol) of azirine rac-14 in 5 mL of CH2Cl2 was stirred at 0 °C for 
2 h. Evaporation of the solvent and purification by CC (AcOEt) yielded 560 mg (96%) of a mixture of (S,S)- and (S,R)-15. Separation of the 
diastereomers by MPLC (AcOEt) gave 215 mg (37%) (S,S)-15 and 205 mg (35%) (S,R)-15, which were crystallized from 
Et2O/hexane/CH2Cl2. (S,R)-15: M.p. 102–102.5 °C. IR: 3300m, 3060w, 2980w, 1705s, 1660s, 1630s, 1530s, 1495s, 1450m, 1265s, 1090m, 
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735m, 700s. 1H-NMR: 7.68 (s, NH), 7.5–7.25 (m, 15 arom. H), 6.49, 5.55 (2s, 2 NH), 5.24, 5.08 (AB, J = 12.4, PhCH2O), 3.75–3.65 (m, 
PhCH2), 3.33, 3.25 (AB, J = 14, PhCH2), 3.22 (br s, NMe2), 1.65, 1.61, 1.56, 1.53 (4s, 4 Me). 13C-NMR: 173.2, 172.2, 171.3 (3s, 3 CO), 
155.3 (s, OCONH), 136.6, 136.3, 136.0 (3s, 3 arom. C), 130.7, 130.5, 128.6, 128.3, 128.2, 127.9, 127.8, 126.9, 126.5 (9d, 15 arom. CH), 
66.9 (t, PhCH2O), 65.7, 60.4, 57.3 (3s, 3 C(α)), 42.6, 41.1 (2t, 2 PhCH2), 38.0 (q, NMe2), 25.8, 24.7, 24.0, 23.1 (4q, 4 Me). CI-MS: 587 (5, 
[M+1]+), 542 (100, [M–NMe2+1]+). 
(S,S)-15: M.p. 94–98 °C. 1H-NMR: 7.69 (s, NH), 7.45–7.15 (m, 15 arom. H), 6.72, 5.38 (2s, 2 NH), 5.02, 5.0.978 (AB, J = 14, PhCH2O), 
3.59, 3.31 (AB, J = 14.0, PhCH2), 3.46, 3.28 (AB, J = 13.9, PhCH2), 3.16 (br s, NMe2), 1.69, 1.57, 1.54, 1.50 (4s, 4 Me). 13C-NMR: 172.9, 
171.8, 171.4 (3s, 3 CO), 155.2 (s, OCONH), 136.6, 136.1, 135.8 (3s, 3 arom. C), 130.5, 130.4, 128.5, 128.2, 128.1, 127.9, 126.8, 126.6 (8d, 
15 arom. CH), 66.9 (t, PhCH2O), 60.7, 60.5, 57.3 (3s, 3 C(α)), 42.1, 41.9 (2t, 2 PhCH2), 38.2 (q, NMe2), 25.3, 24.2, 23.2 (3q, 4 Me).  
 
Z-Aib-(S)-(αMe)Phe-(R)-(αMe)Phe-Aib-N(Me)Ph ((S,R)-16). According to GP 2, to a solution of 140 mg (0.239 mmol) of  (S,R)-15 in 1 mL 
THF was added 1 mL of 6N HCl and the mixture was stirred at 40 °C for 2.5 h. The solution was extracted with CH2Cl2 and water and the 
organic solvent was evaporated. The formation of the peptide acid was confirmed by the spectroscopic data. 1H-NMR: 7.3–7.2, 6.95–6.9 (2m, 
15 arom. H), 6.42, 5.12 (2s, 2 NH), 4.95, 4.92 (AB, J = 12, PhCH2O), 3.50, 3.34 (AB, J = 13.7, PhCH2), 3.16, 3.07 (AB, J = 13.7, PhCH2), 
1.47, 1.39, 1.37, 1.33 (4s, 4 Me). 13C-NMR: 174.8, 174.2, 173.9 (3s, 3 CO), 155,5 (s, OCONH), 136.3, 135.6, 135.3 (3s, 3 arom. C), 130.9, 
130.6, 128.8, 128.6, 128.5, 128.1, 127.3, 126.8 (8d, 15 arom. CH), 67.4 (t, PhCH2O), 60.9, 59.5, 57.4 (3s, 3 C(α)), 42.2, 41.2 (2t, 2 PhCH2), 
25.5, 25.0, 23.0, 22.6 (4q, 4 Me). ESI-MS: 582 ([M+Na]+), 560 ([M+1]+). 
According to GP 1, the peptide acid was dissolved in 2 mL of CHCl3 and treated with 50 mg (0.287 mmol) of azirine 9 at r.t. for 2 d. 
Chromatographic workup (CC, CH2Cl2/MeOH 19:1) gave 161 mg (92%) of (S,R)-16 as a colorless solid. M.p. 96–97 °C. [α]D +25.6 (CHCl3, 
c = 0.11). IR: 3300s (br), 3060w, 3025m, 2980m, 2930m, 1710s, 1680s, 1660s, 1595m, 1530s (br), 1495s, 1455s, 1390m, 1365m, 1265s, 
1090s, 740m, 705s. 1H-NMR: 7.61 (s, NH), 7.25–7.1 (m, 19 arom. H), 6.78 (s, NH), 6.7–6.65 (m, 1 arom. H), 6.40, 5.08 (2s, 2 NH), 4.98, 
4.74 (AB, J = 12, PhCH2O), 3.74, 3.21 (AB, J = 13.8, PhCH2), 3.37 (s, NMe), 2.92, 2.62 (AB, J = 13.7, PhCH2), 1.51, 1.49, 1.43, 1.34, 1.31, 
1.10 (6s, 6 Me). 13C-NMR: 173.6, 173.5, 173.4, 172.6 (4s, 4 CO), 155.3 (s, OCONH), 146.0, 137.5, 135.6, 134.9 (4s, 4 arom. C), 131.2, 
130.2, 128.9, 128.6, 128.5, 127.7, 127.3, 126.4 (8d, 20 arom. CH), 67.2 (t, PhCH2O), 60.6, 59.0, 57.5, 57.1 (4s, 4 C(α)), 43.9, 39.9 (2t, 2 
PhCH2), 40.1 (q, NMe2), 26.2, 25.8, 24.2, 23.9, 21.0 (5q, 6 Me). ESI-MS: 757 ([M+Na]+). 
 
Z-Aib-(S)-(αMe)Phe-(S)-(αMe)Phe-Aib-N(Me)Ph ((S,S)-16). According to GP 2, 124 mg (0.211 mmol) of  (S,S)-15 in 2 mL THF were 
hydrolysed with 1 mL of 6N HCl at 40 °C for 4 h. The solution was extracted with CH2Cl2 and water and the organic solvent was evaporated. 
According to GP 1, the residue was dissolved in CHCl3 (2 mL) and reacted with 50 mg (0.287 mmol) of azirine 9 at r.t. for 2 d. 
Crystallisation from AcOEt/petroleum ether gave 139 mg (90%) of (S,S)-16. M.p. 187–189 °C. [α]D –131.3 (CHCl3, c = 0.094). IR: 3350s, 
3290s, 3065w, 3025w, 2995m, 2940m, 1715s, 1670s, 1645s, 1595w, 1530s, 1495s, 1450m, 1390m, 1365m, 1265s, 1085s, 770m, 750m, 705s. 
1H-NMR: 7.57 (s, NH), 7.35–7.3, 7.25–7.15, 7.1–7.0 (3m, 20 arom. H and 1 NH), 6.00, 5.21 (2s, 2 NH), 4.92, 4.70 (AB, J = 12.0, PhCH2O), 
3.85, 3.50 (AB, J = 13.8, PhCH2), 3.45 (s, NMe), 3.23, 3.19 (AB, J = 14.1, PhCH2), 1.60, 1.59, 1.47, 1.44, 1.32, 1.13 (6s, 6 Me). 13C-NMR: 
173.9, 173.8, 173.7, 172.4 (4s, 4 CO), 155.4 (s, OCONH), 146.0, 137.7, 136.6, 135.5 (4s, 4 arom. C), 131.3, 131.0, 128.9, 128.7, 128.5, 
128.3, 128.0, 127.6, 127.5, 126.8, 126.5, 126.3 (12d, 20 arom. CH), 67.2 (t, PhCH2O), 60.4, 59.7, 57.6, 57.4 (4s, 4 C(α)), 40.1 (q, NMe2), 
39.2, 39.1 (2t, 2 PhCH2), 27.0, 26.6, 25.9, 24.6, 23.7 (5q, 6 Me). ESI-MS: 757 ([M+Na]+). Suitable crystals for the X-ray crystal structure 
determination were obtained from AcOEt/hexane. 
 
4-BrC6H4CO-Aib-(S)-(αMe)Phe-(R)-(αMe)Phe-Aib-N(Me)Ph ((S,R)-17). A mixture of 73 mg (0.10 mmol) of  (S,R)-16, 70 mg Pd/C (10%), 
and 60 mg ammonium formate (HCO2NH4) in 7 mL MeOH was heated to reflux for 15 min. The suspension was filtered (Celite), the solvent 
evaporated and the residue dissolved in AcOEt. Then, 0.6 mL Et3N and 65 mg 4-bromobenzoyl chloride were added and the mixture was 
stirred at 30 °C for 2 h. Extraction with 1N HCl and 1N NaOH, drying of the organic phase (MgSO4), evaporation of the solvent, and 
purification by CC (CH2Cl2/MeOH 19:1) yielded 50 mg (64%) of (S,R)-17. M.p. 218–222 °C. [α]D –18.7 (CHCl3, c = 0.118). IR: 3350s, 
3290s, 3065w, 3025w, 2995m, 2940m, 1715s, 1670s, 1645s, 1595w, 1530s, 1495s, 1450m, 1390m, 1365m, 1265s, 1085s, 770m, 750m, 705s. 
1H-NMR: 7.65 (s, NH), 7.51, 7.45 (AB, J = 8.5, 4 arom. H),  7.25–7.0 (m, 13 arom. H and 2 NH), 6.85–6.8 (m, 2 arom. H), 6.32 (s, NH), 
3.70, 3.20 (AB, J = 13.9, PhCH2), 3.32 (s, NMe), 2.93, 2.81 (AB, J = 13.8, PhCH2), 1.47, 1.46, 1.44, 1.37, 1.35, 1.27 (6s, 6 Me). 13C-NMR: 
174.0, 173.9, 173.8, 172.7 (4s, 4 CO), 165.4 (s, ArCONH), 145.9, 137.4, 135.2, 131.8, 127.2 (5s, 5 arom. C), 131.9, 131.6, 131.1, 130.3, 
129.2, 129.0, 128.6, 128.0, 127.8, 127.5, 127.4, 126.6, 126.5 (13d, 19 arom. CH), 60.6, 59.1, 57.6, 57.4 (4s, 4 C(α)), 43.5, 40.5 (2t, 2 PhCH2), 
40.2 (q, NMe2), 26.0, 25.9, 25.7, 24.1, 24.0, 22.0 (6q, 6 Me). ESI-MS: 806, 804 ([M+Na]+). Suitable crystals for the X-ray crystal structure 




Synthesis of tetrapeptide amides (R,S,R)-20 and (R,R,R)-20 with accumulated Aib units 
(R,S)-4-Bromo-N-{1-benzyl-1-methyl-2-[2-(1-methoxy-1-methylethyl)pyrrolidin-1-yl]benzamide ((R,S)-18. To a solution of 201 mg (1 
mmol) 4-bromobenzoic acid in 2 mL of THF at 0 °C was slowly added a solution of 286 mg (1 mmol) of the azirine (R,S)-3 in 2 mL of THF. 
The mixture was stirred at r.t. overnight and then heated to 67 °C for 3 h. Then, the solvent was evaporated, the residue dissolved in CH2Cl2 
and washed with 5 mL of 1N NaOH. The solvent was evaporated and the residue crystallized from AcOEt/hexane to give 221 mg (45%) of 
(R,S)-18. [α]D –20.7 (CHCl3, c = 1.011). IR: 3290s, 2980s, 2940m, 1665s, 1605s, 1540s, 1475m, 1450m, 1400s, 1300s, 1245m, 1145s, 
1060m, 1015m, 850m, 705s. 1H-NMR: 7.55–7.50 (m, 4 arom. H), 7.4 (br, NH), 7.2–7.15, 7.0–6.95 (2m, 5 arom. H), 4.53 (d, J = 8, CHN), 
4.1–4.05 (m, 1 H), 3.78, 3.40 (AB, J = 14, PhCH2), 3.5–3.35 (m, 1 H), 3.17 (s, MeO), 2.1–2.0 (m, 2 H), 1.9–1.8 (m, 5 H), 1.20, 1.14 (2s, 2 
Me). 13C-NMR: 171.3, 164.8 (2s, 2 CO), 136.7, 134.2 (2s, 2 arom. C), 131.6, 129.9, 128.3, 128.0, 125.8 (5d, 9 arom. CH), 126.7 (s, 1 arom. 
C), 78.5 (s, Me2C), 65.2 (d, CHN), 61.6 (s, C(α)), 49.1 (q, MeO), 48.0, 39.8 (2t, PhCH2, CH2N), 25.2, 23.6 (2t, 2 CH2), 22.6, 22.3, 21.7 (3q, 
3 Me). CI-MS: 489, 487 ([M+1]+). Suitable crystals for the X-ray crystal structure determination were obtained from AcOEt/hexane. 
 
4-BrC6H4CO-(R)-(αMe)Phe-Aib-Aib-(S)-(αMe)Phe-N(Me)PhEt ((R,S,R)-20) and 4BrC6H4CO-(R)-(αMe)Phe-Aib-Aib-(R)-(αMe)Phe-
N(Me)PhEt ((R,R,R)-20). According to GP 2, 125 mg (0.25 mmol) (R,S)-18 were dissolved in 1 mL THF, 1 mL of 6N HCl was added and 
the mixture stirred at 40 °C overnight. The resulting solution was extracted with CH2Cl2 and water, dried, and the solvent evaporated. The 
residue was dissolved in 5 mL of CH2Cl2, 50 mg (0.28 mmol) azirine 9 were added according to GP 1 and the mixture was stirred at r.t. for 2 
h. Then, the solvent was evaporated, the residue dissolved in AcOEt and the product precipitated by addition of petroleum ether. The solid 
material was again dissolved in 1 mL of THF and hydrolysed with 6N HCl at 40 °C for 30 min according to GP 2. After usual workup, the 
residue was dissolved in 4 mL of CH2Cl2 and according to GP 1 reacted with 55 mg (0.31 mmol) azirine 9 at r.t. for 1 h. The solution was 
concentrated, the residue was dissolved in AcOEt and the product precipitated by addition of petroleum ether to give 120 mg (77%) of 4-
BrC6H4CO-(R)-(αMe)Phe-Aib-Aib-N(Me)Ph ((R)-19). 1H-NMR: 7.5–7.45, 7.35–7.25, 7.2–7.15, 7.05–7.0 (4m, 14 arom. H and 1 NH), 6.89, 
6.73 (2s, 2 NH), 4.53 (d, J = 8, CHN), 3.40, 3.23 (AB, J = 13.8, PhCH2), 3.24 (s, NMe), 1.59, 1.44, 1.42, 1.40 (4s, 5 Me). ESI-MS: 645, 643 
([M+Na]+). 
According to GP 2, a solution of 100 mg (0.161 mmol) tripeptide amide (R)-19 in 2 mL of THF was treated with 2 mL of 6N HCl at 40 °C 
for 1 h. After usual workup, the tripeptide acid was dissolved in 5 mL of CH2Cl2, and 2.5 mL of the solution was reacted with 30 mg (0.108 
mmol) azirine (S,R)-2a and (R,R)-2a, respectively, at r.t. overnight. Because the reactions were incomplete, the solvent was evaporated, each 
residue was dissolved in 1.5 mL of CHCl3 and the solutions stirred at r.t. for 3 d. Then, the solvent was again removed and the residue 
crystallized in each case.  
 
4-BrC6H4CO-(R)-(αMe)Phe-Aib-Aib-(S)-(αMe)Phe-N(Me)PhEt ((R,S,R)-20). Yield: 62 mg (95%). M.p. 174–176 °C 
(CHCl3/AcOEt/petroleum ether). [α]D +59.0 (CHCl3, c = 0.105). IR: 3300s (br), 3065w, 3025w, 2995m, 2940m, 1670s (br), 1640s, 1620s, 
1540s, 1500s, 1480s, 1455s, 1395m, 1380s, 1360m, 1320m, 1230m, 1180m, 1070m, 755m, 700s. 1H-NMR: 7.6–7.55, 7.3–7.25, 7.15–7.05 
(3m, 19 arom. H and 3 NH), 6.53 (s, NH), 6.0–5.95 (m, NCHMePh), 3.41, 3.03 (AB, J = 14, PhCH2), 3.04, 2.76 (AB, J = 14, PhCH2), 3.32, 
3.27 (AB, J = 14.3, PhCH2), 2.83 (s, NMe), 1.64, 1.54, 1.39, 1.36 (4s, 4 Me), 1.34 (br, NCHMePh), 1.32, 1.28 (2s, 2 Me). 13C-NMR: 173.9, 
173.4, 173.1, 171.8, 167.0 (5s, 5 CO), 140.8, 137.4, 136.8, 132.0, 128.1 (5s, 5 arom. C), 132.1, 131.1, 130.7, 128.9, 128.4, 128.0, 127.8, 
127.3, 127.0, 126.3 (10d, 19 arom. CH), 60.4, 60.2, 57.5, 57.0 (4s, 4 C(α)),  52.2 (d, NCHMePh), 42.5, 40.7 (2t, 2 PhCH2), 30.3 (q, NMe), 
26.7, 26.0, 25.2, 24.6, 23.2, 22.8, 14.9 (6q, 7Me). ESI-MS: 834, 832 ([M+Na]+). 
 
4-BrC6H4CO-(R)-(αMe)Phe-Aib-Aib-(R)-(αMe)Phe-N(Me)PhEt ((R,R,R)-20). Yield: 56 mg (87%). M.p. 132–134 °C 
(MeOH/AcOEt/petroleum ether). 1H-NMR (MeOD): 7.85–7.8, 7.75–7.7, 7.65–7.6, 7.35–7.3, 7.3–7.2, 7.2–7.15, 7.1–6.95 (7m, 19 arom. H), 
5.94 (q, J = 7, NCHMePh), 3.38 (s, PhCH2), 3.20, 2.85 (AB, J = 13.5, PhCH2), 2.80 (s, NMe), 1.62, 1.59, 1.57 (3s, 3 Me), 1.48 (d, J = 7, 
NCHMePh), 1.43, 1.36, 1.31 (3s, 3 Me). 13C-NMR (MeOD): 182.1, 176.3, 176.1, 173.6, 168.6 (5s, 5 CO), 141.6, 137.7, 137.3, 133.9, 128.9 
(5s, 5 arom. C), 132.7, 132.1, 132.0, 130.4, 129.2, 128.9, 128.5, 128.1, 127.7, 127.6, 127.5 (11d, 19 arom. CH), 61.9, 60.8, 58.4, 57.9 (4s, 4 





 X-ray Crystal-Structure Determination of (R,S)-18, (S,S,R)-12, (S,R,R)-12, (S,R,R)-13, (S,S)-16 and (S,R)-17 (see Table 3 
and Figs. 2 – 7)5).  
 
The measurements were made at low temperature using graphite-monochromated MoKα radiation (λ 0.71073 Å) on a Rigaku AFC5R 
diffractometer fitted to a 12-kW rotating-anode generator. The intensities of three standard reflections were measured after every 150 
reflections and remained stable throughout the data collection. The intensities were corrected for Lorentz and polarization effects. Azimuthal 
scans of several reflections indicated no need for an absorption correction. Equivalent reflections, other than Friedel pairs, were merged.  
The data collection and refinement parameters are given in Table 3 and views of the molecules are shown in Figs. 2 – 7.  The structures were 
solved as described for the individual structures below. For all structures, the non-H-atoms were refined anisotropically. Unless indicated 
otherwise below, amide H-atoms were generally placed in the positions indicated by difference electron density maps and their positions 
were allowed to refine together with individual isotropic displacement parameters. Otherwise, and for all other H-atoms, they were placed in 
geometrically calculated positions and refined by using a riding model, with Uiso(H) = 1.2Ueq(parent atom) (1.5Ueq for Me groups). The 
refinement of each structure was carried out on F2 by using full-matrix least-squares procedures, which minimized the function Σw(Fo2 – Fc2) 2. 
The weighting scheme was based on counting statistics and included a factor to downweight the intense reflections. Neutral atom scattering 
factors for non-hydrogen atoms were taken from Maslen, Fox and O'Keefe[75], and the scattering factors for H-atoms were taken from 
Stewart, Davidson and Simpson[76]. Anomalous dispersion effects were included in Fc[77]; the values for f' and f" were those of Creagh and 
McAuley[78]. The values of the mass attenuation coefficients are those of Creagh and Hubbel[79]. The SHELXL-2018 program[80] was used for 
all calculations. 
The structure of (R,S)-18 was solved by Patterson methods using SHELXS86[81], which revealed the position of the Br-atom.  All 
remaining non-hydrogen atoms were located in a Fourier expansion of the Patterson solution. Refinement of the absolute structure 
parameter[82, 83] yielded a value of -0.026(7), which confidently confirms that the refined model represents the true enantiomorph.  
The structure of (S,S,R)-12 was solved by direct methods using SHELXS86, which revealed the positions of all non-hydrogen atoms. 
One reflection, whose intensity was considered to be an extreme outlier, was omitted from the final refinement. The absolute configuration 
could not be determined reliably and, therefore, the enantiomer used in the refinement was based on the known (5S,14R)-configuration of the 
molecule. 
The structure of (S,R,R)-12 was solved by using the fragment orientation and translation routines of DIRDIF92[84], which revealed the 
positions of most non-hydrogen atoms. The starting fragment consisted of three peptide units from the backbone of the related structure of 
(S,S,R)-12. All remaining non-hydrogen atoms were located in a subsequent difference electron density map. The crystal was quite weakly 
diffracting and of sub-standard quality with some of the reflection profiles exhibiting shoulders. The number of observed reflections and the 
precision of the geometric parameters are quite low, but the structure is clearly defined. The enlarged atomic displacement parameters for 
some atoms may in part be due to the influence of the poor crystal on the data. The asymmetric unit contains two molecules of the peptide 
plus two ethyl acetate molecules. The atomic coordinates of the molecules were tested carefully for a relationship from a higher symmetry 
space group using the program PLATON[85], but none could be found. Peptide molecule B exhibits disorder of the terminal methylbenzyl 
group and of the terminal benzoyl ring. The ethyl groups of the solvent molecules are also disordered. Two sets of positions were defined for 
the ring atoms of both disordered groups in molecule B, plus the methyl group of the methylbenzyl group, and the ring atoms were 
constrained to an ideal hexagon. The site occupation factors of the major conformations of these groups refined to 0.611(9) and 0.555(17), 
respectively. Similarity restraints were applied to the chemically equivalent bond lengths involving all disordered C-atoms that were not 
constrained, while neighboring atoms within and between each conformation of the disordered butyl groups were restrained to have similar 
atomic displacement parameters. The amide H-atoms were included as riding in calculated positions. Five reflections, whose intensities were 
considered to be extreme outliers, were omitted from the final refinement. The absolute configuration could not be determined reliably and, 
therefore, the enantiomer used in the refinement was based on the known (5S)-configuration of the molecule. 
 The diffracting power of the crystal of (S,R,R)-13 fell off sharply with increasing diffraction angle and no discernible diffraction 
intensities were observed for 2θ > 50°.The structure was solved by Patterson methods using SHELXS86, which revealed the position of the 
Br-atom. All remaining non-hydrogen atoms were located in a Fourier expansion of the Patterson solution. The asymmetric unit contains one 
molecule of the peptide plus one disordered AcOEt molecule.  The solvent disorder could not be modelled satisfactorily, so an ordered model 
with enlarged atomic displacement ellipsoids was employed. The amide H-atoms were included as riding in calculated positions. Three 
                                                                                    
5)  CCDC-1992397-1992402 contain the supplementary crystallographic data for this paper. These data can be obtained free of charge 
from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/structures. 
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reflections, whose intensities were considered to be extreme outliers, were omitted from the final refinement. Refinement of the absolute 
structure parameter yielded a value of -0.001(8), which confidently confirms that the refined model represents the true enantiomorph. 
The structure of (S,S)-16 was solved using the fragment orientation and translation routines of DIRDIF92, which revealed the 
positions of most non-hydrogen atoms. The starting fragment consisted of three peptide units from the backbone of the related structure of 
(S,S,R)-12. All remaining non-hydrogen atoms were located in a subsequent difference electron density map. The asymmetric unit contains 
two molecules of the peptide plus one water molecule with full site occupancy and one water molecule which seems to be present only in 
approximately 30% of its sites and it site occupancy was fixed at 0.3. The atomic coordinates of the molecules were tested carefully for a 
relationship from a higher symmetry space group using the program PLATON, but none could be found. The positions of the H-atoms of the 
water molecules could not be determined reliably and were not included in the model. The absolute configuration could not be determined 
unequivocally and, therefore, the enantiomer used in the refinement was based on the configuration of the molecule known from the 
synthesis. 
The diffracting power of the crystal of (S,R)-17 fell off sharply with increasing diffraction angle and no discernible diffraction 
intensities were observed for 2θ > 50°. The structure was solved by Patterson methods using DIRDIF92, which revealed the positions of the 
Br-atoms. All remaining non-hydrogen atoms were located in several steps through Fourier expansions of the partial solution. The 
asymmetric unit contains two independent molecules of the peptide plus one ordered and one disordered molecule of AcOEt. The atomic 
coordinates of the molecules were tested carefully for a relationship from a higher symmetry space group using the program PLATON, but 
none could be found. The disordered AcOEt molecule involves end-to-end flipping of the molecule. Two sets of positions were defined for 
carbonyl O-atom and the methylene C-atom and the site occupation factor of the major conformation of the molecule refined to 0.641(10). 
Similarity restraints were applied to the chemically equivalent bond lengths involving all disordered atoms, while neighboring atoms within 
and between each conformation of the molecule were restrained to have similar atomic displacement parameters. The amide H-atoms were 
included as riding in calculated positions. One reflection, whose intensity was considered to be an extreme outlier, was omitted from the final 
refinement. Refinement of the absolute structure parameter yielded a value of –0.008(4), which confidently confirms that the refined model 






Table 3.  Crystallographic Data for compounds (R,S)-18, (S,S,R)-12, (S,R,R)-12, (S,R,R)-13, (S,S)-16 and (S,R)-17 
________________________________________________________________________________________________________ 
 (R,S)-18 (S,S,R)-12 (S,R,R)-12 
________________________________________________________________________________________________________ 
Crystallized from AcOEt/hexane AcOEt/hexane AcOEt/hexane 
Empirical formula C25H31BrN2O3 C45H55N5O6  C45H55N5O6.C4H8O2 
Formula weight 487.43 761.94 850.04 
Crystal color, habit colorless, needle colorless, prism colorless, prism  
Crystal dimensions [mm] 0.15 × 0.18 × 0.48 0.18 × 0.20 × 0.50 0.25 × 0.30 × 0.42 
Temperature [K] 173(1) 173(1) 173(1) 
Crystal system orthorhombic orthorhombic triclinic 
Space group P212121 P212121 P1 
Z 4 4 2 
Reflections for cell determination 23 25  22 
2θ range for cell determination [°] 35–39  32–40 25–37 
Unit cell parameters a [Å] 11.384(4) 16.770(3) 10.802(8) 
 b [Å] 18.452(3) 22.601(8) 12.641(7) 
 c [Å] 11.0453(19) 10.918(4) 17.614(8) 
 α [°] 90 90 97.17(5) 
 β [°] 90 90 92.09(5) 
 γ [°] 90 90 100.46(6) 
 V [Å3] 2320.1(10) 4138(2) 2342(2) 
F(000)  1016 1632 912 
Dx [g cm
-3] 1.395 1.223 1.205 
µ(MoKα) [mm-1] 1.801  0.0820 0.0820 
Scan type ω ω ω 
2θ(max) [°] 60.0 50.0 50.2 
Total reflections measured 7988 4753 8661 
Symmetry independent reflections 6214 4619 8661 
Rint 0.030 0.037 - 
Reflections with I > 2σ(I)  4401  3750 5913 
Reflections used in refinement 6214 4618 8656 
Parameters refined; restraints 288; 0 529; 4 1240; 431 
Final R(F)  [I > 2σ (I) reflections] 0.0417  0.0410 0.0574 
 wR(F2) (all data) 0.0954  0.1146 0.1773 
Weighting parameter (a; b)[a] 0.0348; 0 0.0569; 0.4774 0.0787; 2.0554 
Goodness of fit 1.023 1.067 1.031 
Final ∆max/σ 0.000 0.000 0.000 
∆ρ (max; min) [e Å–3] 0.41; –0.43 0.23; –0.19 0.43; –0.29 
_____________________________________________________________________________________________________ 





Table 3.  Crystallographic Data for Compounds (R,S)-18, (S,S,R)-12, (S,R,R)-12, (S,R,R)-13, (S,S)-16 and (S,R)-17 (continued) 
_________________________________________________________________________________________________________ 
 (S,R,R)-13 (S,S)-16 (S,R)-17  
_________________________________________________________________________________________________________ 
Crystallized from AcOEt/petroleum ether AcOEt/hexane AcOEt/CH2Cl2 
Empirical formula        C44H52BrN5O5.C4H8O2    C43H51N5O6.0.65H2O C42H48BrN5O5.C4H8O2 
Formula weight 898.92 745.60 870.86 
Crystal color, habit colorless, prism colorless, prism colorless, prism  
Crystal dimensions [mm] 0.40 × 0.40 × 0.42 0.17 × 0.40 × 0.50 0.20 × 0.38 × 0.45 
Temperature [K] 173(1) 173(1) 173(1) 
Crystal system orthorhombic monoclinic triclinic 
Space group P212121 P21 P1 
Z 4 4 2 
Reflections for cell determination 21 25  25 
2θ range for cell determination [°] 33–39 26–36 24–26 
Unit cell parameters a [Å] 19.245(3) 10.913(5) 11.554(3) 
 b [Å] 22.139(5) 35.161(8) 11.830(2) 
 c [Å] 11.028(4) 11.442(6) 18.188(4) 
 α [°] 90 90 87.167(18) 
 β [°] 90 111.57(4) 74.47(2) 
 γ [°] 90 90 69.928(18) 
 V [Å3] 4698(2) 4083(3) 2247.2(9) 
F(000)  1896 1594 916 
Dx [g cm
-3] 1.271 1.213 1.287 
µ(MoKα) [mm-1] 0.929  0.0820 0.969 
Scan type ω ω ω 
2θ(max) [°] 50.0 55.0 55.1 
Total reflections measured 7210 10007 15334 
Symmetry independent reflections 6584 9511 14712 
Rint 0.076 0.025 0.025 
Reflections with I > 2σ(I)  3889  7034 9364 
Reflections used in refinement 6581 9511 14711 
Parameters refined; restraints 560; 0  1037; 2 1100; 70 
Final R(F)  [I > 2σ (I) reflections] 0.0539  0.0497 0.0455 
 wR(F2) (all data) 0.1546  0.1406 0.1176 
Weighting parameter (a; b)[a] 0.0688; 2.4765 0.0724; 0.3323 0.0388; 1.8090 
Goodness of fit 1.019 1.035 1.007 
Final ∆max/s 0.000 0.000 0.000 
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Twitter Text 
Sterically congested tetrapeptide amides containing two Aib and two (αMe)Phe unit were prepared via the ‘azirine/oxazolone 
method’ and their solid-state conformations determined by X-ray crystallography. 
 
